FORMA Therapeutics Competitors and Similar CompaniesClear all
FORMA Therapeutics's competitors and similar companies include Oryzon Genomics, Alkahest, Kura Oncology and Iovance Biotherapeutics.
 FORMA Therapeutics FORMA Therapeutics is a biopharmaceutical company intended for the discovery, development, and commercialization of transformative medicines. |  Oryzon Genomics Oryzon Genomics is a clinical stage biopharmaceutical company that discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. |  Kura Oncology Kura Oncology is a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers. |  Iovance Biotherapeutics Iovance Biotherapeutics (formerly Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes. | ||
Founding Date | Founding Date 2008 | Founding Date 2000 | Founding Date 2014 | Founding Date 2007 | Founding Date 2013 |
Type | Type Public | Type Public | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Watertown, US HQ | Locations Cornellà de Llobregat, ES HQ Madrid, ES Cambridge, US | Locations San Carlos, US HQ | Locations San Diego, US HQ Boston, US San Diego, US San Diego, US | Locations San Carlos, US HQ New York, US Philadelphia, US Philadelphia, US Tampa, US |
Employees | Employees 77 | Employees 46 | Employees 47 | Employees 5712% increase | Employees 14868% increase |
Valuation ($) | Valuation ($) 998.7 m | Valuation ($) 115.5 m | Valuation ($) N/A | Valuation ($) 1.3 b | Valuation ($) 3.3 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $53.9m (FY, 2024) | Revenue (est.) $164.1m (FY, 2024) |
Cost of goods | Cost of goods N/A | Cost of goods €302k (FY, 2024) | Cost of goods N/A | Cost of goods N/A | Cost of goods $124m (FY, 2024) |
Gross profit | Gross profit N/A | Gross profit (€89k) (FY, 2024) | Gross profit N/A | Gross profit N/A | Gross profit $40.1m (FY, 2024) |
Net income | Net income ($173m) (FY, 2021) | Net income (€3.7m) (FY, 2024) | Net income N/A | Net income ($174m) (FY, 2024) | Net income ($372.2m) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised $ 142.5m | Total funding raised N/A | Total funding raised $ 41m | Total funding raised N/A | Total funding raised $ 100m |
For sources of this data, please see the company profile
View Company Profiles
Oryzon Genomics
HQ
Cornellà de Llobregat, ES
Employees
46
Oryzon Genomics is a clinical stage biopharmaceutical company that discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases.
View company
Alkahest
HQ
San Carlos, US
Employees
47
Alkahest is a biopharmaceutical company specializing in plasma therapies.
View companyKura Oncology
HQ
San Diego, US
Employees
57↑ 12% increase
Kura Oncology is a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers.
View companyIovance Biotherapeutics
HQ
San Carlos, US
Employees
148
Iovance Biotherapeutics (formerly Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes.
View company